Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
GLPL-1 agonists are typically prescribed only for those patients with a BMI greater than 30
The typical patient has a soft-tissue injury that stalled: they completed physical therapy, have no surgical indication, but are still symptomatic at 8 to 12 weeks
Expert Opin Biol Ther
In a statement to Insider, Novo Nordisk, the company that makes Wegovy and Ozempic, said that Gila monsters and the discovery of exendin-4 "did not have anything to do with our decision to develop long-acting GLP-1 receptor agonists" for obesity, because "that was based on GLP-1 biology in humans." But the company also said that "the GLP-1-like effect of exendin-4" in Gila monsters was "an important contribution to the field," as it led to the development of the very first injectable drug of its kind
US$ 26.60
US$ 26.01
US$ 28.88
